Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Memorial Day. We will reopen on Tuesday, May 31st.

Thank you for your patience.

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-Estrogen Receptor α (Ser167) (D1A3) Rabbit mAb 5587 100 µl
Western Blotting
H 66 Rabbit IgG
Estrogen Receptor α (D8H8) Rabbit mAb 8644 100 µl
Western Blotting Immunoprecipitation Immunofluorescence Chromatin Immunoprecipitation
H 66 Rabbit IgG

Product Description

PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.


Estrogen receptor α (ERα), a member of the steroid receptor superfamily, contains highly conserved DNA binding and ligand binding domains (1). Through its estrogen-independent and estrogen-dependent activation domains (AF-1 and AF-2, respectively), ERα regulates transcription by recruiting coactivator proteins and interacting with general transcriptional machinery (2). Phosphorylation at multiple sites provides an important mechanism to regulate ERα activity (3-5). Ser104, 106, 118, and 167 are located in the amino-terminal transcription activation function domain AF-1, and phosphorylation of these serine residues plays an important role in regulating ERα activity. Ser118 may be the substrate of the transcription regulatory kinase CDK7 (5). Ser167 may be phosphorylated by p90RSK and Akt (4,6). According to the research literature, phosphorylation at Ser167 may confer tamoxifen resistance in breast cancer patients (4).


1.  Chen D et al. (2000) Mol Cell 6, 127–37

2.  Chen, D. et al. (1999) Mol Cell Biol 19, 1002-15.

3.  Mangelsdorf, D.J. et al. (1995) Cell 83, 835-9.

4.  Campbell, R.A. et al. (2001) J Biol Chem 276, 9817-24.

5.  Glass, C.K. and Rosenfeld, M.G. (2000) Genes Dev 14, 121-41.

6.  Joel, P.B. et al. (1998) Mol Cell Biol 18, 1978-84.


Entrez-Gene Id 2099
Swiss-Prot Acc. P03372

Protein Specific References

Chen D et al. (2000) Mol Cell 6, 127–37

Métivier R et al. (2002) EMBO J 21, 3443–53

Dutertre M and Smith CL (2003) Mol Endocrinol 17, 1296–314

Lu Q et al. (2003) J Biol Chem 278, 4639–45

Murphy L et al. (2004) Clin Cancer Res 10, 1354–9

Murphy LC et al. (2004) Clin Cancer Res 10, 5902–6

Cui Y et al. (2004) Cancer Res 64, 9199–208

Staka CM et al. (2005) Endocr Relat Cancer 12 Suppl 1, S85–97

Chen J et al. (2005) Blood 106, 328–37

Medunjanin S et al. (2005) J Biol Chem 280, 33006–14

Yamashita H et al. (2005) Breast Cancer Res 7, R753–64

Gburcik V et al. (2005) Mol Cell Biol 25, 3421–30

Shah YM and Rowan BG (2005) Mol Endocrinol 19, 732–48

Kim MY et al. (2006) Mol Endocrinol 20, 1479–93

Kuske B et al. (2006) Endocr Relat Cancer 13, 1121–33

Sekine Y et al. (2007) Oncogene 26, 6038–49

Britton DJ et al. (2008) J Am Soc Mass Spectrom 19, 729–40

Thomas RS et al. (2008) J Mol Endocrinol 40, 173–84

Kok M et al. (2009) J Natl Cancer Inst 101, 1725–9

Ma Y et al. (2010) Mol Endocrinol 24, 76–90

He X et al. (2010) Oncogene 29, 2238–51

Cañas A et al. (2012) Breast Cancer Res 14, R153

Bhatt S et al. (2012) Mol Cell Biol 32, 1928–43

Chen D et al. (2000) Mol Cell 6, 127–37

Métivier R et al. (2002) EMBO J 21, 3443–53

Dutertre M and Smith CL (2003) Mol Endocrinol 17, 1296–314

Lu Q et al. (2003) J Biol Chem 278, 4639–45

Murphy L et al. (2004) Clin Cancer Res 10, 1354–9

Murphy LC et al. (2004) Clin Cancer Res 10, 5902–6

Cui Y et al. (2004) Cancer Res 64, 9199–208

Staka CM et al. (2005) Endocr Relat Cancer 12 Suppl 1, S85–97

Chen J et al. (2005) Blood 106, 328–37

Medunjanin S et al. (2005) J Biol Chem 280, 33006–14

Yamashita H et al. (2005) Breast Cancer Res 7, R753–64

Gburcik V et al. (2005) Mol Cell Biol 25, 3421–30

Shah YM and Rowan BG (2005) Mol Endocrinol 19, 732–48

Kim MY et al. (2006) Mol Endocrinol 20, 1479–93

Kuske B et al. (2006) Endocr Relat Cancer 13, 1121–33

Sekine Y et al. (2007) Oncogene 26, 6038–49

Britton DJ et al. (2008) J Am Soc Mass Spectrom 19, 729–40

Thomas RS et al. (2008) J Mol Endocrinol 40, 173–84

Kok M et al. (2009) J Natl Cancer Inst 101, 1725–9

Ma Y et al. (2010) Mol Endocrinol 24, 76–90

He X et al. (2010) Oncogene 29, 2238–51

Cañas A et al. (2012) Breast Cancer Res 14, R153

Bhatt S et al. (2012) Mol Cell Biol 32, 1928–43


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PhosphoPlus is a trademark of Cell Signaling Technology, Inc.

12108
PhosphoPlus® Estrogen Receptor α (Ser167) Antibody Duet